This appears to be characteristic of KDM4 inhibitors, as QC8222 has entered a trial for advanced metastatic cancers (93), and the pan-KDM inhibitor JIB-04 is currently in clinical trial against breast leptomeningeal carcinomatosis, due to KDM4A and C inhibition (94). This evidence concerns the gene KDM4A and metastatic malignant neoplasm.